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Gestational ageEarly fetal and placental MSCs have translationally-advantageous characteristics compared to later pregnancy
MSCs. During the ﬁrst trimester, the fetus and placenta grow rapidly with divergent developmental require-
ments, but studies comparing mesenchymal stem cells (MSCs) from different origins have paid little attention
to the effect of gestational age over this temporal window. Here we present the transcriptome through ﬁrst tri-
mester development ofMSC isolated from fetal bonemarrow (BM) or placental structures. Sampleswere collect-
edweekly from 8 to 12 weeks. The rawmicroarray data are available on the ArrayExpress database (www.ebi.ac.
uk/arrayexpress) under accession number E-TABM-1224. Additionally, the data have been integrated into the
stem cell collaboration platform www.Stemformatics.org. These data provide a valuable resource for develop-
mental biology and stem cell investigation.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).SpeciﬁcationsOrganism/cell line/tissue Human
Sex Male & female
Sequencer or array type Illumina HumanHT-12 v4 BeadChip
Data format Raw and normalized
Experimental factors Tissues and gestational age comparison
Experimental features Transcriptome of fetal bone marrow (BM) or placental
MSCs through ﬁrst trimester
Consent Ethically-approved sample collection and processing.
Anonymised results.
Sample source location Brisbane, AustraliaDirect link to deposited data
http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1224/
http://www.stemformatics.org/datasets/view/6063Research, The University of
ia.
s).
. This is an open access article underExperimental design, materials and methods
Sample collection
The Human Research Ethics Committees of the Royal Brisbane and
Women's Hospital and the University of Queensland approved the tis-
sue collection. Women gave written informed consent for the use of
fetal tissue for research purposes after clinically-indicated termination
of pregnancy in compliance with national research guidelines.
Fetal MSC from bone marrow (BM) and placental tissues [chorionic
membrane (CM), and chorionic villi (CV)] were obtained from three do-
nors at ﬁve time points across the ﬁrst trimester (8, 9, 10, 11 and
12 weeks). Developmental age was expressed in gestational weeks, as
per convention and as used clinically (postconceptual age plus two
weeks). Gestational age of the fetal and placental tissues collected was
determined by an ultrasound (Sonoscope 3.5–4.5 MHz), using a
crown rump length between 7 and 11 weeks, and biparietal diameter
thereafter, expressed in days and rounded to the nearest half week.
Stem cell isolation and culture
Fetal BM-MSCs were prepared by ﬂushing fetal long bones using a
21-gauge syringe [1]. Single cell suspensions of fetal BM were washedthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Eagle's medium (DMEM) (Invitrogen). MSCs from CM and CVwere iso-
lated by enzymatic digestion with dispase (2.4 U/ml) and collagenase
(240 U/ml) using protocols adapted from Steigman et al. 2007 [2].
MSCswere then cultured in DMEM supplementedwith 10% fetal bovine
serum, antibiotic and antimycotic solution (100×, Invitrogen), at 37 °C
with 5% CO2. Isolated MSCs were characterized by a typical cell surface
phenotype and differentiation capacity. All MSCs used were between
passages 1 and 6.Differentiation assays
Differentiation potential of each MSC source was performed accord-
ing to the previously published methods [3]. Staining for both
adipogenic and osteogenic assays was visualized using a bright ﬁeld
phase contrast microscopy.
For adipogenesis, 2 × 105 MSCs were seeded in 6 well plates until
conﬂuent, and differentiation induced by culturing the cells in
adipogenic media containing; indomethacin (60 μM), dexamethasone
(1 μM), insulin (5 μg/ml) and isobutylmethylxanthine (IBMX)
(0.5 mM). All reagents were from Sigma-Aldrich. After 21 days, cells
were ﬁxed with 4% paraformaldehyde with PBS and stained with Oil
Red O. Adipogenic differentiation was determined by the appearance
of Oil Red O indicating the formation of lipid vacuoles, characteristic of
adipogenic cells.Fig. 1. Immunophenotyping of fetal bonemarrow (BM), chorionicmembrane (CM) and chorion
and negative expression of surface proteins. Similar expression levels were observed for each s
CD31, CD34 and CD45. Red Peak represents marker of interested, black peak represents isotypOsteogenic differentiationwas induced by culturing 3× 105 cells in 6
well plates in the presence of osteogenic induction media containing
dexamethasone (0.1 μM), β-glycerol phosphate (10 mM) and L-ascor-
bate-2-phosphate (0.2 mM) for 21 days. All reagents were from
Sigma-Aldrich. Cells were ﬁxed in 4% paraformaldehyde in PBS and
stained with Alizarin red. Differentiation was determined by the ap-
pearance of red deposits, representing areas of mineralized calcium.
Flow cytometry
All MSCs were immunophenotyped by ﬂow cytometry [3]. MSCs
were washed and resuspended in PBS containing 2% FBS. 100 μl of
cells (1 × 106) were incubated with cell surface antigen CD11b-APC,
CD14-Pe/Cy5, CD29-Pe, CD31-APC, CD34-Pe, CD44-FITC, CD45-Pe/Cy5,
CD73-APC, CD73-APC, CD90-FITC and CD105-FITC or the appropriate
isotype controls (eBiosciences or BD Biosciences) for 20 mins at 4 °C.
Cells were acquired using Gallios Flow Cytometer and analyzed using
Kaluza software (Beckman Coulter).
T cell proliferation assay
The mitogen-driven T cell proliferation assay was performed by
stimulating PBMC with 1 μg/ml Phytohemagglutinin (PHA) in ﬂat-
bottom 96-well plates (Nunc) in a total of 200 μM RPMI 1640 supple-
mented with 10% heat-inactivated FCS and 1% penicillin/streptomycinic villi (CV) by ﬂowcytometric analysis. Representative histograms demonstrating positive
ource. The cells were positive for CD29, CD44, CD90, CD73 and negative for CD11b, CD14,
e control.
A) B) C)
Fig. 2. Representative images of multi-differentiation potential of ﬁrst trimester fetal bonemarrow (BM), chorionic villi (CV) and chorionicmembrane (CM) at 8–12weeks. Adipogenesis
was determined using oil red O staining of lipid droplets after 21 days in adipogenic media, and osteogenesis using alizarin red staining for mineral matrix deposition after 21 days in os-
teogenic media. Scale bar = 50 μM.
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were cultured with or without 1.5 × 104 MSC in the presence of
0.1 μg/ml PHA and PBMC. After 4 days in culture, 1 μCi 3H-Thymidine
was added to each well and samples were incubated for further 6 h at
37 °C in a humidiﬁed CO2 incubator. Cells were then harvested onto
glass ﬁber ﬁlter mats using a Skatron harvester. 3H-Thymidine incorpo-
ration was measured using a β-plate scintillation counter. Proliferation
was represented as the incorporated radioactivity in counts per minute
(CPM). Results are expressed as the mean of triplicate values ± SE.Fig. 3. T cell proliferation was reduced by BM-MSC compared to CM-MSC (*, p= 0.0161)
and CV-MSC (***, p= 0.0002). CM-MSC showed greater ability to suppress proliferation
compared to CV-MSC (*, p= 0.0371). Expressed as mean CPM+/−SE.MSC phenotyping
Human MSCs from fetal BM, placental CM, and placental CV were
isolated at 8, 9, 10, 11 and 12 weeks. Universally, each MSC source
met the criteria set by the International Society for Cellular Therapy
[4] being plastic adherent, ﬁbroblastic in morphology and expressed
the variousMSCmarkers. Using ﬂow cytometry, cell surfacemarker ex-
pression for each source and gestational age was shown to be similar,
indicating the immunophenotype was not affected by gestational age
or MSC source. MSCs expressed CD29, CD44, CD73, CD90 and CD105
and were negative for hematopoietic and endothelial cell markers
(CD14, CD34, CD45 and CD31) (Fig. 1).
Each MSC source and gestation was examined for its ability to
differentiate into adipocytes and osteocytes under appropriate induc-
tive culture conditions. Results showed some variability between
MSC sources. BM-MSC at each gestation were consistently superior at
differentiating into osteocytes compared to CV-MSC and CM-MSC.
Early BM-MSC and CM-MSC (8 & 9 weeks) were considerably slower
to undergo adipogenesis compared to later gestations (10–12) andCV-MSC were particularly poor at adipogenic differentiation at each
gestational age examined (Fig. 2).
To investigate the functional immunosuppressive properties of fetal-
MSC and placental MSC, in vitro mitogen-driven proliferation assays
were used to evaluate their ability to suppress T cell proliferation. PHA
was used as a standard mitogen to trigger proliferation of lymphocytes.
The effect of MSC on T cell proliferation was evaluated by incubating
PBMC with either BM-MSC, CM-MSC or CV-MSC. As expected, all MSC
sources suppressed mitogen-driven proliferation of PBMC, however,
BM-MSC showed a greater reduction of PBMC proliferation compared
to CM-MSC (p = 0.0161) and CV-MSC (p = 0.0002), while CM-MSC
Fig. 4. Principal Component Analysis (detected probes only). Components 1 (93.2% variance) and 2 (2.1% variance); Legend: MSC source indicated by color: bone marrow (BM) (blue);
chorionic membrane (CM) (red); chorionic villi (CV) (green). Label number indicates gestational stage (weeks).
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(p= 0.0371) (Fig. 3).
RNA extraction
Total RNAwas extracted from all theMSC samples using the RNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's
instructions. Total RNA yield was determined using Nanodrop 1000,
and the quantity and quality were validated using the Agilent 2100
Bioanalyzer (Agilent Technologies).
Illumina HumanHT-12 v4 BeadChip microarray
To determine whether there was a niche or gestational effect on
MSC, we analyzed the transcriptome proﬁles of three MSC sources:
bonemarrow (BM)-MSC, chorionic membrane (CM)-MSC and chorion-
ic villi (CV)-MSC using the Illumina HumanHT-12 v4 BeadChip array
(Illumina — BD-103-0204 San Diego, CA 92122 USA). MSC isolated
from bone marrow (BM)-MSC, chorionic membrane (CM)-MSC
and chorionic villi (CV)-MSC were studied longitudinally over 5 weeks
(8–12 weeks gestation). We analyzed three donors at each gestational
age from each source (n = 45 total MSC donors).
Brieﬂy, total RNA (500 ng)was converted to biotinylated cRNAusing
Illumina TotalPrep RNA Ampliﬁcation Kit (Invitrogen — AMIL1791) (as
per proprietary instructions) and hybridized to HumanHT-12 v4
BeadChip (Illumina — BD-103-0204). The hybridized BeadChip was
washed and scanned with the Illumina BeadStation System.
Microarray data
Raw data were processed using GenomeStudio version 2011.1
and exported with no preprocessing. Background correction and nor-
malization was performed using the Bioconductor package ‘lumi’ [5].
Microarray data were deposited into ArrayExpress (Accession Number
E-TABM-1224). Principal Component Analysis is shown in Fig. 4.
Additionally, the data have been integrated into a public portal,
Stemformatics [6]. Here all the microarray data can be visualized
and compared with 100+ other stem cell datasets (http://www.
stemformatics.org).Author contributions
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